Actemra 162 MG/0.9 ML syringe 0.9ML
Ended Awarded Last action
- Contract number
- SPE2DR26FU830
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,889
Award facts
- Contract value 100% obligated
- $22,888.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,888.50 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on December 17, 2025, with an ultimate completion date of December 18, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions, representing the type of specialty pharmaceutical products that support military and federal healthcare systems.
This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support Defense Health Agency operations and other federal healthcare systems worldwide. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains an extensive portfolio of delivery orders across multiple therapeutic domains, demonstrating its capacity to fulfill federal procurement requirements for both routine and specialized medical commodities.
Quick answers
Who was awarded contract SPE2DR26FU830?
SPE2DR26FU830 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FU830 worth?
The government has obligated $22,889 on SPE2DR26FU830.
Is contract SPE2DR26FU830 an order under another contract?
Yes. SPE2DR26FU830 is a delivery order under SPE2DR25D1053, an indefinite delivery contract.
Was contract SPE2DR26FU830 competed?
The extent of competition for SPE2DR26FU830 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award